Medpace Holdings, Inc. logo
Medpace Holdings, Inc. (MEDP)
Compare

Medpace Holdings, Inc. (MEDP) Price/FCF Ratio: 18.12

popular:market cap|pe ratio|revenue|price history|total return

Is Medpace Holdings, Inc.’s Price/FCF ratio high or low?

Medpace Holdings, Inc.'s Price/FCF ratio of 18.12 is 21% below its 5-year average of 22.81, near the low end of its 5-year range (15.44–33.16).

17.44% below its 12-month average of 21.95.

P/E Ratio|FCF Growth|Operating Margin|All Metrics

MEDP Price/FCF Ratio Chart

MEDP Price/FCF Ratio
18.12+4.38% 1Y
Zoom

MEDP Average Price/FCF Ratio Chart

MEDP Current vs Average Price/FCF Ratio Chart

MEDP Price/FCF Ratio Metrics

PRICE/FCF RATIO

18.12

PRICE/FCF RATIO AVG TTM

21.95

PRICE/FCF RATIO AVG 3Y

22.58

PRICE/FCF RATIO AVG 5Y

22.81

PRICE/FCF RATIO AVG 10Y

20.70

PRICE/FCF RATIO AVG 15Y

N/A

PRICE/FCF RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

-17.44%

CURRENT VS 3Y AVG

-19.75%

CURRENT VS 5Y AVG

-20.56%

CURRENT VS 10Y AVG

-12.45%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

MEDP Competitors' Price/FCF Ratio

NAMEMARKET CAPPRICE/FCF RATIOTTM3Y5Y
Medpace Holdings, Inc. (MEDP)$13.18B18.1221.9522.5822.81
The Cooper Companies, Inc. (COO)vs ›$13.14B23.0633.8971.5957.99
Solventum Corporation (SOLV)vs ›$13.26BN/A116.9265.0165.01
DaVita Inc. (DVA)vs ›$13.46B9.648.038.738.76
Align Technology, Inc. (ALGN)vs ›$12.86B18.7419.0730.9540.44
Revvity, Inc. (RVTY)vs ›$11.29B22.9321.96204.95127.12
Baxter International Inc. (BAX)vs ›$10.57B14.7639.0430.9730.26
Walgreens Boots Alliance, Inc. (WBA)vs ›$10.37B17.8617.1329.6417.62
Hologic, Inc. (HOLX)vs ›$16.97B17.1816.1518.1814.60
Charles River Laboratories International, Inc. (CRL)vs ›$8.90B23.1216.3522.7128.30

Free Cash Flow Valuation

P/FCF Ratio

18.1

FCF Yield

5.52%

Medpace Holdings, Inc. Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Medpace Holdings, Inc. Price/FCF Ratio FAQ

What is the Price/FCF ratio for Medpace Holdings, Inc. (MEDP)?
The Price/FCF ratio for MEDP stock is 18.12.
Is Medpace Holdings, Inc.'s Price/FCF ratio high or low?
Medpace Holdings, Inc.'s Price/FCF ratio of 18.12 is 21% below its 5-year average of 22.81, near the low end of its 5-year range (15.44–33.16).
What is the TTM average Price/FCF ratio for Medpace Holdings, Inc. (MEDP)?
The TTM average Price/FCF ratio for MEDP stock is 21.95.
What is the 3Y average Price/FCF ratio for Medpace Holdings, Inc. (MEDP)?
The 3Y average Price/FCF ratio for MEDP stock is 22.58.
What is the 5Y average Price/FCF ratio for Medpace Holdings, Inc. (MEDP)?
The 5Y average Price/FCF ratio for MEDP stock is 22.81.
What is the 10Y average Price/FCF ratio for Medpace Holdings, Inc. (MEDP)?
The 10Y average Price/FCF ratio for MEDP stock is 20.70.

Medpace Holdings, Inc. Price/FCF Ratio History

DATEPRICE/FCF RATIO
2026-06-1618.12
2026-06-1518.35
2026-06-1218.34
2026-06-1118.65
2026-06-1018.28
2026-06-0918.32
2026-06-0817.97
2026-06-0517.83
2026-06-0418.01
2026-06-0317.70
2026-06-0217.49
2026-06-0117.72
2026-05-2917.55
2026-05-2817.59
2026-05-2716.80
2026-05-2616.84
2026-05-2216.99
2026-05-2116.88
2026-05-2016.56
2026-05-1916.48
2026-05-1816.51
2026-05-1516.30
2026-05-1416.45
2026-05-1316.63
2026-05-1216.48
2026-05-1116.38
2026-05-0816.64
2026-05-0716.83
2026-05-0616.75
2026-05-0516.89
2026-05-0416.37
2026-05-0116.39
2026-04-3016.43
2026-04-2916.23
2026-04-2816.08
2026-04-2716.54
2026-04-2416.12
2026-04-2315.44
2026-04-2220.78
2026-04-2121.04
2026-04-2021.60
2026-04-1721.28
2026-04-1621.07
2026-04-1521.19
2026-04-1421.25
2026-04-1320.49
2026-04-1020.17
2026-04-0920.50
2026-04-0821.28
2026-04-0720.78
2026-04-0620.27
2026-04-0220.37
2026-04-0120.01
2026-03-3119.63
2026-03-3018.81
2026-03-2718.44
2026-03-2619.07
2026-03-2519.08
2026-03-2418.83
2026-03-2318.67
2026-03-2018.49
2026-03-1918.84
2026-03-1818.59
2026-03-1718.60
2026-03-1618.54
2026-03-1318.41
2026-03-1218.14
2026-03-1119.52
2026-03-1019.08
2026-03-0919.56
2026-03-0619.23
2026-03-0519.18
2026-03-0419.04
2026-03-0319.02
2026-03-0218.70
2026-02-2718.46
2026-02-2618.27
2026-02-2517.90
2026-02-2418.07
2026-02-2318.19
2026-02-2018.55
2026-02-1918.25
2026-02-1818.23
2026-02-1717.50
2026-02-1317.49
2026-02-1217.00
2026-02-1117.33
2026-02-1018.23
2026-02-0922.39
2026-02-0622.89
2026-02-0522.86
2026-02-0423.71
2026-02-0324.01
2026-02-0224.84
2026-01-3024.60
2026-01-2925.04
2026-01-2825.25
2026-01-2725.43
2026-01-2625.42
2026-01-2324.83
2026-01-2225.60
2026-01-2126.21
2026-01-2025.44
2026-01-1625.80
2026-01-1526.10
2026-01-1426.03
2026-01-1325.69
2026-01-1225.30
2026-01-0925.12
2026-01-0825.34
2026-01-0725.89
2026-01-0625.71
2026-01-0524.78
2026-01-0224.11
2025-12-3123.72
2025-12-3024.02
2025-12-2924.07
2025-12-2623.97
2025-12-2424.15
2025-12-2324.06
2025-12-2224.13
2025-12-1924.00
2025-12-1823.66
2025-12-1723.52
2025-12-1623.59
2025-12-1523.61
2025-12-1223.56
2025-12-1123.91
2025-12-1023.68
2025-12-0922.97
2025-12-0823.19
2025-12-0523.14
2025-12-0423.00
2025-12-0324.34
2025-12-0224.65
2025-12-0124.83
2025-11-2825.02
2025-11-2625.61
2025-11-2525.83
2025-11-2426.12
2025-11-2124.99
2025-11-2024.75
2025-11-1925.01
2025-11-1824.92
2025-11-1724.73
2025-11-1424.92
2025-11-1324.97
2025-11-1225.23
2025-11-1125.45
2025-11-1025.35
2025-11-0724.88
2025-11-0625.01
2025-11-0525.29
2025-11-0425.10
2025-11-0325.08
2025-10-3124.70
2025-10-3024.51
2025-10-2924.68
2025-10-2824.51
2025-10-2725.19
2025-10-2425.56
2025-10-2325.19
2025-10-2228.44
2025-10-2128.39
2025-10-2028.32
2025-10-1727.47
2025-10-1627.12
2025-10-1526.76
2025-10-1426.89
2025-10-1327.44
2025-10-1026.08
2025-10-0926.98
2025-10-0827.63
2025-10-0727.67
2025-10-0627.59
2025-10-0327.70
2025-10-0227.89
2025-10-0128.30
2025-09-3026.75
2025-09-2926.05
2025-09-2625.85
2025-09-2525.39
2025-09-2425.87
2025-09-2325.81
2025-09-2225.91
2025-09-1925.94
2025-09-1826.11
2025-09-1725.90
2025-09-1625.53
2025-09-1525.83
2025-09-1225.53
2025-09-1125.89
2025-09-1024.80
2025-09-0925.26
2025-09-0825.60
2025-09-0525.34
2025-09-0425.09
2025-09-0325.04
2025-09-0224.63
2025-08-2924.74
2025-08-2824.60
2025-08-2724.63
2025-08-2624.41
2025-08-2524.29
2025-08-2224.12
2025-08-2123.59
2025-08-2024.23
2025-08-1924.04
2025-08-1824.08
2025-08-1523.82
2025-08-1423.86
2025-08-1324.35
2025-08-1223.89
2025-08-1123.40
2025-08-0822.60
2025-08-0722.31
2025-08-0622.39
2025-08-0522.70
2025-08-0422.50
2025-08-0122.01
2025-07-3122.23
2025-07-3022.78
2025-07-2923.30
2025-07-2823.57
2025-07-2523.28
2025-07-2423.71
2025-07-2322.76
2025-07-2224.85
2025-07-2117.81
2025-07-1817.99
2025-07-1718.41
2025-07-1618.16
2025-07-1518.03
2025-07-1418.48
2025-07-1118.66
2025-07-1018.93
2025-07-0918.51
2025-07-0818.60
2025-07-0718.39
2025-07-0318.54
2025-07-0218.80
2025-07-0118.52
2025-06-3018.10
2025-06-2717.92
2025-06-2617.69
2025-06-2517.94
2025-06-2418.18
2025-06-2317.80
2025-06-2017.84
2025-06-1817.46
2025-06-1717.18
2025-06-1617.36
2025-06-1317.20
2025-06-1217.53
2025-06-1117.43
2025-06-1017.64
2025-06-0917.20
2025-06-0617.10
2025-06-0516.93
2025-06-0418.04

Showing the most recent 260 of 2,475 data points. The chart above shows the full history.

Related Metrics

P/E RatioFCF GrowthOperating MarginAll Metrics

About Medpace Holdings, Inc.

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

Cincinnati, OH
5,900 employees
www.medpace.com
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
August James Troendle
View full financials